Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,819 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
Kim JW, Kim JH, Im SA, Lee KH, Kim JS, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA. Kim JW, et al. Among authors: kim ty, kim js, kim jh. Cancer Chemother Pharmacol. 2013 Nov;72(5):1023-9. doi: 10.1007/s00280-013-2268-9. Epub 2013 Sep 15. Cancer Chemother Pharmacol. 2013. PMID: 24036907
Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies.
Kim I, Yoon SS, Lee KH, Keam B, Kim TM, Kim JS, Kim HG, Oh MD, Han KS, Park MH, Park S, Kim BK. Kim I, et al. Among authors: kim hg, kim tm, kim js, kim bk. Clin Transplant. 2006 Jul-Aug;20(4):496-503. doi: 10.1111/j.1399-0012.2006.00512.x. Clin Transplant. 2006. PMID: 16842528 Clinical Trial.
Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.
Han HS, Kim JS, Park JH, Jeon YK, Lee KW, Oh DY, Kim JH, Park SY, Im SA, Kim TY, Park IA, Bang YJ. Han HS, et al. Among authors: kim ty, kim js, kim jh. J Korean Med Sci. 2009 Oct;24(5):910-7. doi: 10.3346/jkms.2009.24.5.910. Epub 2009 Sep 24. J Korean Med Sci. 2009. PMID: 19794992 Free PMC article.
Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients.
Kim JS, Baek JY, Park SR, Choi IS, Kim SI, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ, Kim NK. Kim JS, et al. Among authors: kim dw, kim ty, kim si, kim nk. Cancer Res Treat. 2004 Dec;36(6):372-6. doi: 10.4143/crt.2004.36.6.372. Epub 2004 Dec 31. Cancer Res Treat. 2004. PMID: 20368831 Free PMC article.
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA. Kim JW, et al. Among authors: kim yj, kim ty, kim js, kim jh. Cancer Chemother Pharmacol. 2013 Jul;72(1):109-15. doi: 10.1007/s00280-013-2174-1. Epub 2013 May 15. Cancer Chemother Pharmacol. 2013. PMID: 23673443
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
Park S, Keam B, Kim SH, Kim KH, Kim YJ, Kim JS, Kim TM, Lee SH, Kim DW, Lee JS, Heo DS. Park S, et al. Among authors: kim yj, kim dw, kim sh, kim js, kim tm, kim kh. Cancer Res Treat. 2015 Oct;47(4):630-7. doi: 10.4143/crt.2014.244. Epub 2015 Feb 16. Cancer Res Treat. 2015. PMID: 25687850 Free PMC article.
15,819 results
You have reached the last available page of results. Please see the User Guide for more information.